Omicron strain ‘has greater growth rate and may be more transmissible’
The BA.2 strain is a sub-lineage of the now dominant original Omicron variant known as BA.1.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A strain of Omicron that is being monitored by experts has a greater growth rate than the original version and transmission of it among household contacts is likely to be higher, the UK Health Security Agency (UKHSA) has said.
The BA.2 strain is a sub-lineage of the now dominant original Omicron variant known as BA.1.
Last week it was designated a variant under investigation and on Friday UKHSA said that as of January 24 there had been 1,072 confirmed cases identified in England.
The agency said that BA.2 had an increased growth rate compared to BA.1 in all regions of England where there were enough cases to assess it.
It added that while growth rates can be overestimated in early analyses of a new variant, “the apparent growth advantage is currently substantial”.
Contact tracing analysis suggests that between December 27 and January 11 transmission was likely to be higher among contacts of BA.2 cases in households at 13.4%, than those for contacts of other Omicron cases (10.3%).
But the agency warned that the findings should be interpreted with caution as early findings can change quickly when new variants are identified.
A preliminary assessment found no evidence that vaccines would be any less effective against symptomatic disease for BA.2.
There is currently no data on the severity of the strain.
Dr Susan Hopkins, chief medical adviser for UKHSA, said: “We now know that BA.2 has an increased growth rate which can be seen in all regions in England.
“We have also learnt that BA.2 has a slightly higher secondary attack rate than BA.1 in households.
“Although hospitalisations and deaths remain low, cases are still high in some areas and some age groups so it’s important that we continue to act cautiously as restrictions are lifted.
“Consider wearing a face covering when in crowded places. Take a vaccine to protect yourself against Covid-19. If you have any symptoms, take a test.”
UKHSA also published analyses related to the original Omicron strain BA.1.
Where variant information was available, the majority of intensive care unit (ICU) admissions from November 24 last year to January 19 were for Delta.
The data further suggested that overall numbers of ICU admissions have decreased over time, but where Omicron admissions data was available, they increased from 9% to more than 50% in the most recent week.
According to UKHSA, while there was a rapid increase in infections in care homes during December, there has not been an associated increase in hospital admissions.
UKHSA said the findings suggest the current wave of Omicron infections is unlikely to lead to a major surge in severe disease in care home populations with high levels of vaccine coverage and/or natural immunity.
The numbers of BA.2 in this study were limited and no inferences can be made regarding the strain, it added.
Jonathan Ball, professor of molecular virology, University of Nottingham said: “It’s still early days, but the evidence so far suggests that BA.2 may be more transmissible than its close relative Omicron.
“However, the key issues are whether this variant is associated with more severe disease and if it can escape immunity delivered by vaccines.
“Early indicators suggest that the vaccines will provide similar levels of protection as we have seen for Omicron, so this is good news.
“Whether or not it causes more severe disease will become apparent as more data is collected.”